Current Appointments & Affiliations
Associate Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2018 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Journal Article J Clin Oncol · December 10, 2025 The phase II PHAROS study previously showed that encorafenib plus binimetinib has antitumor activity in patients with BRAF V600E-mutant metastatic non-small cell lung cancer (mNSCLC). In PHAROS, 98 patients (59 treatment-naïve; 39 previously treated) recei ... Full text Link to item CiteA Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.
Journal Article Cancer · November 1, 2025 BACKGROUND: Treatment options for patients with advanced non-small cell lung cancer (NSCLC) with disease progression following immune checkpoint inhibitor (ICI) and platinum-based chemotherapy are limited. GT103 is a fully human immunoglobulin G3 monoclona ... Full text Link to item CiteUpdated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report.
Journal Article J Thorac Oncol · October 2025 INTRODUCTION: The PHAROS primary analysis revealed robust antitumor activity and acceptable safety with encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report results after 18 months of additional follow-up. ME ... Full text Link to item CiteRecent Grants
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of CRB-601, a Monoclonal Antibody against Integrin ?v?8, in Patients with Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Corbus Pharmaceuticals, Inc. · 2025 - 2030A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer (SCLC)(DeLLphi-309)
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2025 - 2030SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 express
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2025 - 2030View All Grants
Education, Training & Certifications
Indiana University, School of Medicine ·
2008
M.D.